TL/DR –
TransMedics Group has announced the appointment of Fernando Araujo as Chief Financial Officer, effective from September 21, 2026. Araujo, who brings with him over 20 years of finance leadership experience from GE HealthCare, General Electric, and 3M, will succeed Gerardo Hernandez, who is set to transition to the role of Commercial Strategic Advisor for Latin America. Concurrent with the announcement, TransMedics reiterated its full-year revenue guidance for 2026, falling between $737 million and $757 million.
TransMedics Appoints New CFO and Reconfirms 2026 Revenue Outlook
TransMedics Group, Inc., the global leader in portable warm perfusion for transplantable organs, has appointed Fernando Araujo as Chief Financial Officer (CFO) effective September 21, 2026. Araujo, with extensive experience from GE HealthCare, General Electric, and 3M, will support the next phase of TransMedics’ global growth.
Araujo succeeds Gerardo Hernandez, who will lead TransMedics’ expansion into Latin America. Alongside this announcement, TransMedics also reconfirmed its full-year revenue guidance for 2026.
Fernando Araujo’s Career Highlights
Araujo, a global finance executive, has over 20 years of experience in the healthcare, industrial, and energy sectors. Most notably, he served as CFO for GE HealthCare’s Advanced Imaging Solutions segment. Araujo has also held a number of senior finance and CFO roles at General Electric and 3M.
A New Chapter for TransMedics
“Fernando’s experience in scaling finance operations at complex, global healthcare businesses is well aligned with TransMedics’ future,” said Waleed Hassanein, M.D., President and CEO. Araujo said, “TransMedics has differentiated technology and multiple near-term potential growth catalysts. I look forward to creating lasting value for shareholders.”
TransMedics also recognizes Gerardo Hernandez’s contributions over the past two years as he transitions to lead an early entry into Latin America.
2026 Financial Outlook for TransMedics
TransMedics reaffirmed its full-year 2026 revenue guidance of $737 million to $757 million, representing about 22% to 25% year-over-year growth. This estimation does not include revenue from the recent investment in PAD Aviation Service GmbH. The company will revisit this outlook during its third quarter 2026 results.
Upcoming Investor Conferences
TransMedics management will participate in fireside chats at the Morgan Stanley 24th Annual Global Healthcare Conference and the Baird 2026 Global Healthcare Conference. Live and archived webcasts are available in the “Investors” section of the TransMedics website.
About TransMedics Group, Inc.
TransMedics, the world’s leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation, was founded to meet the need for more and better organs for transplantation. They have developed technologies to preserve organ quality, assess organ viability before transplant, and potentially increase the use of donor organs for end-stage heart, lung, and liver failure treatment.
Contact Information for Investors
Investors can contact Brian Johnston and Hannah Jeffrey at 332-895-3222 or [email protected] for more information. TransMedics routinely posts information that may be important to investors on their website.
—
Read More Health & Wellness News ; US News